287 related articles for article (PubMed ID: 34648139)
1. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
Zebardast A; Hosseini P; Hasanzadeh A; Latifi T
Mol Biol Rep; 2022 Jan; 49(1):647-656. PubMed ID: 34648139
[TBL] [Abstract][Full Text] [Related]
2. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Lorenzi JCC; Park S; Schmidt F; Wang Z; Huang Y; Luo Y; Nair MS; Wang P; Schulz JE; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Munster V; Ho DD; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
Nature; 2021 Jul; 595(7866):278-282. PubMed ID: 34098567
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.
Yang Y; Li F; Du L
J Nanobiotechnology; 2024 May; 22(1):304. PubMed ID: 38822339
[TBL] [Abstract][Full Text] [Related]
4. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2.
Tang Q; Owens RJ; Naismith JH
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835020
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
[TBL] [Abstract][Full Text] [Related]
6. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
Güttler T; Aksu M; Dickmanns A; Stegmann KM; Gregor K; Rees R; Taxer W; Rymarenko O; Schünemann J; Dienemann C; Gunkel P; Mussil B; Krull J; Teichmann U; Groß U; Cordes VC; Dobbelstein M; Görlich D
EMBO J; 2021 Oct; 40(19):e107985. PubMed ID: 34302370
[TBL] [Abstract][Full Text] [Related]
8. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
[TBL] [Abstract][Full Text] [Related]
9. The development of
Ye G; Gallant J; Zheng J; Massey C; Shi K; Tai W; Odle A; Vickers M; Shang J; Wan Y; Du L; Aihara H; Perlman S; LeBeau A; Li F
Elife; 2021 Aug; 10():. PubMed ID: 34338634
[TBL] [Abstract][Full Text] [Related]
10. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
[TBL] [Abstract][Full Text] [Related]
11. Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization.
Zhang R; Huang L; Zhang X; Yu Y; Liang T; Wang H; Zhang X; Hu D; Wang B; Wang Y; Jiang J; Yu X
J Proteome Res; 2024 May; 23(5):1559-1570. PubMed ID: 38603467
[TBL] [Abstract][Full Text] [Related]
12. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
13. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
14. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
15. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
[TBL] [Abstract][Full Text] [Related]
16. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
Cornish K; Huo J; Jones L; Sharma P; Thrush JW; Abdelkarim S; Kipar A; Ramadurai S; Weckener M; Mikolajek H; Liu S; Buckle I; Bentley E; Kirby A; Han X; Laidlaw SM; Hill M; Eyssen L; Norman C; Le Bas A; Clarke J; James W; Stewart JP; Carroll M; Naismith JH; Owens RJ
Open Biol; 2024 Jun; 14(6):230252. PubMed ID: 38835241
[TBL] [Abstract][Full Text] [Related]
18. Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.
Golcuk M; Hacisuleyman A; Erman B; Yildiz A; Gur M
J Chem Inf Model; 2021 Oct; 61(10):5152-5160. PubMed ID: 34581563
[TBL] [Abstract][Full Text] [Related]
19. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.
Valenzuela Nieto G; Jara R; Watterson D; Modhiran N; Amarilla AA; Himelreichs J; Khromykh AA; Salinas-Rebolledo C; Pinto T; Cheuquemilla Y; Margolles Y; López González Del Rey N; Miranda-Chacon Z; Cuevas A; Berking A; Deride C; González-Moraga S; Mancilla H; Maturana D; Langer A; Toledo JP; Müller A; Uberti B; Krall P; Ehrenfeld P; Blesa J; Chana-Cuevas P; Rehren G; Schwefel D; Fernandez LÁ; Rojas-Fernandez A
Sci Rep; 2021 Feb; 11(1):3318. PubMed ID: 33558635
[TBL] [Abstract][Full Text] [Related]
20. Preparing for the Future - Nanobodies for Covid-19?
Sasisekharan R
N Engl J Med; 2021 Apr; 384(16):1568-1571. PubMed ID: 33826817
[No Abstract] [Full Text] [Related]
[Next] [New Search]
